Hemorrhage, Disseminated Intravascular Coagulopathy, and Thrombosis Complications Among Critically Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study
Jonathon P Fanning,Natasha Weaver,Robert B Fanning,Matthew J Griffee,Sung-Min Cho,Mauro Panigada,Nchafatso G Obonyo,Akram M Zaaqoq,Hannah Rando,Yew Woon Chia,Bingwen Eugene Fan,Declan Sela,Davide Chiumello,Silvia Coppola,Ahmed Labib,Glenn J R Whitman,Rakesh C Arora,Bo S Kim,Anna Motos,Antoni Torres,Ferran Barbé,Giacomo Grasselli,Alberto Zanella,Eric Etchill,Asad Ali Usman,Maximilian Feth,Nicole M White,Jacky Y Suen,Gianluigi Li Bassi,Giles J Peek,John F Fraser,Heidi Dalton,COVID-19 Critical Care Consortium
DOI: https://doi.org/10.1097/CCM.0000000000005798
2023-05-01
Abstract:Objectives: To determine the prevalence and outcomes associated with hemorrhage, disseminated intravascular coagulopathy, and thrombosis (HECTOR) complications in ICU patients with COVID-19. Design: Prospective, observational study. Setting: Two hundred twenty-nine ICUs across 32 countries. Patients: Adult patients (≥ 16 yr) admitted to participating ICUs for severe COVID-19 from January 1, 2020, to December 31, 2021. Interventions: None. Measurements and main results: HECTOR complications occurred in 1,732 of 11,969 study eligible patients (14%). Acute thrombosis occurred in 1,249 patients (10%), including 712 (57%) with pulmonary embolism, 413 (33%) with myocardial ischemia, 93 (7.4%) with deep vein thrombosis, and 49 (3.9%) with ischemic strokes. Hemorrhagic complications were reported in 579 patients (4.8%), including 276 (48%) with gastrointestinal hemorrhage, 83 (14%) with hemorrhagic stroke, 77 (13%) with pulmonary hemorrhage, and 68 (12%) with hemorrhage associated with extracorporeal membrane oxygenation (ECMO) cannula site. Disseminated intravascular coagulation occurred in 11 patients (0.09%). Univariate analysis showed that diabetes, cardiac and kidney diseases, and ECMO use were risk factors for HECTOR. Among survivors, ICU stay was longer (median days 19 vs 12; p < 0.001) for patients with versus without HECTOR, but the hazard of ICU mortality was similar (hazard ratio [HR] 1.01; 95% CI 0.92-1.12; p = 0.784) overall, although this hazard was identified when non-ECMO patients were considered (HR 1.13; 95% CI 1.02-1.25; p = 0.015). Hemorrhagic complications were associated with an increased hazard of ICU mortality compared to patients without HECTOR complications (HR 1.26; 95% CI 1.09-1.45; p = 0.002), whereas thrombosis complications were associated with reduced hazard (HR 0.88; 95% CI 0.79-0.99, p = 0.03). Conclusions: HECTOR events are frequent complications of severe COVID-19 in ICU patients. Patients receiving ECMO are at particular risk of hemorrhagic complications. Hemorrhagic, but not thrombotic complications, are associated with increased ICU mortality.